Integra LifeSciences (NASDAQ:IART) Rating Lowered to Market Perform at Oppenheimer

Integra LifeSciences (NASDAQ:IART) was downgraded by analysts at Oppenheimer from an “outperform” rating to a “market perform” rating in a report released on Tuesday, Marketbeat.com reports.

Other equities analysts also recently issued reports about the stock. Wells Fargo & Company downgraded shares of Integra LifeSciences from an “overweight” rating to an “equal weight” rating and dropped their price target for the stock from $45.00 to $25.00 in a research note on Tuesday. JMP Securities dropped their price objective on Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating on the stock in a report on Thursday, February 29th. Citigroup raised shares of Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 target price for the company in a research report on Wednesday, April 3rd. Truist Financial reduced their price objective on shares of Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating for the company in a research note on Friday, March 1st. Finally, StockNews.com lowered Integra LifeSciences from a “buy” rating to a “hold” rating in a report on Tuesday, April 30th. Three analysts have rated the stock with a sell rating, six have given a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $36.80.

Integra LifeSciences Trading Down 0.7 %

NASDAQ IART opened at $24.91 on Tuesday. The firm’s 50 day moving average price is $32.67 and its two-hundred day moving average price is $38.15. The stock has a market cap of $1.96 billion, a price-to-earnings ratio of 30.01, a PEG ratio of 0.87 and a beta of 1.17. Integra LifeSciences has a twelve month low of $22.36 and a twelve month high of $50.78. The company has a debt-to-equity ratio of 0.94, a quick ratio of 2.18 and a current ratio of 3.45.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings results on Monday, May 6th. The life sciences company reported $0.55 earnings per share for the quarter, meeting the consensus estimate of $0.55. The firm had revenue of $368.90 million for the quarter, compared to analyst estimates of $361.96 million. Integra LifeSciences had a return on equity of 15.19% and a net margin of 4.39%. Integra LifeSciences’s quarterly revenue was down 3.2% on a year-over-year basis. During the same period in the previous year, the firm earned $0.74 earnings per share. Equities analysts anticipate that Integra LifeSciences will post 3.19 EPS for the current year.

Institutional Trading of Integra LifeSciences

A number of hedge funds have recently bought and sold shares of the stock. Swiss National Bank grew its position in Integra LifeSciences by 0.9% during the third quarter. Swiss National Bank now owns 161,994 shares of the life sciences company’s stock worth $6,187,000 after buying an additional 1,500 shares in the last quarter. Cooke & Bieler LP increased its position in shares of Integra LifeSciences by 4.4% during the fourth quarter. Cooke & Bieler LP now owns 2,834,604 shares of the life sciences company’s stock valued at $123,447,000 after purchasing an additional 120,410 shares during the period. Cardinal Capital Management raised its stake in shares of Integra LifeSciences by 1.6% in the fourth quarter. Cardinal Capital Management now owns 22,101 shares of the life sciences company’s stock valued at $962,000 after purchasing an additional 347 shares in the last quarter. Deerfield Management Company L.P. Series C bought a new position in Integra LifeSciences in the third quarter worth $43,034,000. Finally, Assenagon Asset Management S.A. acquired a new stake in Integra LifeSciences during the third quarter worth $25,443,000. 84.78% of the stock is owned by institutional investors.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.